Clinical Trial Update: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine [Phase 1, Phase 2]

View source ↗

Summary

Completion of a Phase 1/Phase 2 safety and immunogenicity study of a therapeutic vaccine for genital herpes caused by HSV-2, conducted by Genocea Biosciences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes

Drugs mentioned

• GEN-003

Snippet

Sponsor: Genocea Biosciences, Inc. | Conditions: Genital Herpes Simplex Type 2 | Phase 1, Phase 2 | Status: COMPLETED